Colleen Moretti

An interim analysis of the PALLAS study showed that adding Ibrance to endocrine therapy, compared to endocrine therapy alone, after initial treatment ended for patients with HR-positive, HER2-negative, early-stage breast cancer did not extend the length of time before a patient’s disease recurred.

Treatment with immuno-oncology therapies induces better responses in younger patients with small cell lung cancer, compared to older patients.

Avastin, in combination with carboplatin plus paclitaxel (types of chemotherapy), improved progression-free survival and overall survival compared with those who received chemotherapy alone for patients with untreated advanced mucosal melanoma.

In a phase 2 study of 24 patients with biliary cancer, Aliqopa in combination with Gemzar and chemotherapy led to a six-month progression-free survival rate of 51% with a median overall survival of 13.7 months.

People recently diagnosed with cancer may be at an increased risk of contracting COVID-19 and experiencing worse outcomes than those who have never had a cancer diagnosis. The association was heightened in Black patients.

Combination treatment with Opdivo and Yervoy may have better overall survival rates for patients with metastatic uveal melanoma.

Women who reported using oral contraceptives had a decreased risk of endometrial and ovarian cancer, compared to those who never used the hormone medications. The data also indicated the association extended up to three decades after patients stopped using the contraceptives.

For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.

Patients with hepatocellular carcinoma who live in low-income and rural households are less likely to receive high quality care and therefore are more likely to be diagnosed with an advanced stage cancer.

Patients with ALK-positive non-small-cell lung cancer who received Lorbrena reported better quality of life and had longer progression-free survival than patients who received Xalkori.

Men who are receiving androgen deprivation therapy treatment for prostate cancer experience higher levels of fatigue and depression when compared to men who are not receiving treatment and who have no history of cancer.

Lynparza demonstrates a significantly longer duration of survival compared Xtandi or Zytiga for men with metastatic prostate cancer, one study found.

Over the last 30 years, cases of childhood liver cancer have increased in the United States, Australia and a Canadian province.

Dr. Barry Tong, a genetic counselor in the cancer genetics and prevention program at UCSF, discusses what genetic cancer testing is, the different types of testing, different results, and why going to a genetic counselor beforehand is so important.

Both younger and older women being treated for early breast cancer with chemotherapy are experiencing the same levels of symptom severity and find it a great concern as it interferes with their daily activities.

Women with ovarian cancer report a better quality of life when treated with a combination of Keytruda, Avastin and oral metronomic cyclophosphamide.

Highlighting a positive prognosis and improving education in treatment risk could result in lowering the overtreatment of older women who develop early-stage, hormone receptor-positive breast cancer.

National guidelines recommend initial surveillance colonoscopy one year after colorectal cancer surgery, but only 57.5% of patients received one in this study due to racial disparities.

Cancer impacts the entire family, and spouses acting as caregivers are experiencing depression and anxiety, without seeking help.

Mortality rate for patients with cancer decreases due to Medicaid expansion for patients with newly diagnosed breast, colorectal and lung cancer.

Dr. Mindy Goldman from the UCSF Hellen Diller Comprehensive Care Center, discusses sexual side effects that cancer survivors face, and offers medication and lifestyle fixes to promote healthy and safe sexual encounters.

Researchers try new drug combination to improve overall survival in patients with recurrent high-grade glioma, but are unsuccessful.

More than half of the patients with breast cancer who took part in an education-only or exercise-based intervention program remained lymphedema free 18 months following surgery to remove one or more of their lymph nodes.

After a median follow-up of 9.9 months, 38% of the trial participants experienced some degree of tumor shrinkage after receiving Opdivo in combination with Yervoy.

Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.

An artificial intelligence-based algorithm within the electronic medical record provided real-time and accurate predictions of the short-term mortality rate of patients with cancer, outperforming all other prognostic incidences commonly used.

Machine learning may be used to predict disease progression in patients with advanced melanoma.

Women with breast cancer who undergo fertility preservation with breast cancer are more likely to give birth than those who do not, researchers report.

We have all been told we should stay off our phone before bed, but this study proves that the outdoor light at night is truly harmful long term and could increase the risk of non-Hodgkin lymphoma.